These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32209248)

  • 1. A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States.
    Chang LJ; Hedrick J; Christensen S; Pan J; Jordanov E; Dhingra MS
    Vaccine; 2020 Apr; 38(19):3560-3569. PubMed ID: 32209248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study.
    Díez-Domingo J; Simkó R; Icardi G; Chong CP; Zocchetti C; Syrkina O; Bchir S; Bertrand-Gerentes I
    Infect Dis Ther; 2024 Aug; 13(8):1835-1859. PubMed ID: 38955966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study.
    Zambrano B; Peterson J; Deseda C; Julien K; Spiegel CA; Seyler C; Simon M; Hoki R; Anderson M; Brabec B; Áñez G; Shi J; Pan J; Hagenbach A; Von Barbier D; Varghese K; Jordanov E; Dhingra MS
    Pediatr Res; 2023 Sep; 94(3):1035-1043. PubMed ID: 36899125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) in Meningococcal Vaccine-Naïve Participants across a Broad Age Range (2-55 Years) in Japan: a Phase III Randomized Study.
    Matsuoka O; Ujiie M; Kikuchi H; Otake S; Chansinghakul D; Inoue T; Varghese K; Sirisuphmitr N; Hashiguchi T; Zambrano B; Nakama T; Frago C; Jordanov E; Dhingra MS
    Jpn J Infect Dis; 2023 May; 76(3):174-182. PubMed ID: 36724939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial.
    Knuf M; Rämet M; Breinholt Stærke N; Bertrand-Gerentes I; Thollot Y; B'Chir S; Arroum H; Oster P
    Hum Vaccin Immunother; 2022 Nov; 18(5):2052657. PubMed ID: 35445641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study.
    Áñez G; Hedrick J; Simon MW; Christensen S; Jeanfreau R; Yau E; Pan J; Jordanov E; Dhingra MS
    Hum Vaccin Immunother; 2020 Jun; 16(6):1292-1298. PubMed ID: 32209015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study.
    Piazza FM; Virta M; Paassilta M; Ukkonen B; Ahonen A; Esteves-Jaramillo A; Forsten A; Seppa I; Ding J; Neveu D; Jordanov E; Dhingra MS
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-10. PubMed ID: 34085900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT)
    van der Vliet D; Vesikari T; Sandner B; Martinón-Torres F; Muzsay G; Forsten A; Adelt T; Diaz Gonzalez C; Simko R; B'Chir S; Neveu D; Jordanov E; Dhingra MS
    Epidemiol Infect; 2021 Feb; 149():e50. PubMed ID: 33541457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2-9 Years of Age: A Phase III, Randomized Study.
    Baccarini CI; Simon MW; Brandon D; Christensen S; Jordanov E; Dhingra MS
    Pediatr Infect Dis J; 2020 Oct; 39(10):955-960. PubMed ID: 32852352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: A Phase III randomized study.
    Dhingra MS; Peterson J; Hedrick J; Pan J; Neveu D; Jordanov E
    Vaccine; 2020 Jul; 38(33):5194-5201. PubMed ID: 32565344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study.
    Vesikari T; Borrow R; Forsten A; Findlow H; Dhingra MS; Jordanov E
    Hum Vaccin Immunother; 2020 Jun; 16(6):1306-1312. PubMed ID: 32233959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study.
    Kirstein J; Pina M; Pan J; Jordanov E; Dhingra MS
    Hum Vaccin Immunother; 2020 Jun; 16(6):1299-1305. PubMed ID: 32233961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ≥59 years: A phase III randomized study.
    Robertson CA; Jacqmein J; Selmani A; Galarza K; Oster P
    Hum Vaccin Immunother; 2023 Dec; 19(1):2160600. PubMed ID: 36632042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Tdap upon antibody response to meningococcal polysaccharide when administered before, with or after the quadrivalent meningococcal TT-conjugate vaccine (coadministered with the 13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj pilgrims: A randomised controlled trial.
    Tashani M; Alfelali M; Barasheed O; Alqahtani AS; Heron L; Wong M; Rashid H; Findlow H; Borrow R; Booy R
    Vaccine; 2018 Jul; 36(29):4375-4382. PubMed ID: 29880243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in ≥56-year-olds: A Phase III randomized study.
    Esteves-Jaramillo A; Koehler T; Jeanfreau R; Neveu D; Jordanov E; Singh Dhingra M
    Vaccine; 2020 Jun; 38(28):4405-4411. PubMed ID: 32387012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents.
    Muse D; Christensen S; Bhuyan P; Absalon J; Eiden JJ; Jones TR; York LJ; Jansen KU; O'Neill RE; Harris SL; Perez JL
    Pediatr Infect Dis J; 2016 Jun; 35(6):673-82. PubMed ID: 26974889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.
    Rivera L; Schwarz TF; Kim KH; Kim YK; Behre U; Cha SH; Jo DS; Lee J; Lee JS; Cheuvart B; Jastorff A; Van der Wielen M
    Vaccine; 2018 Jul; 36(31):4750-4758. PubMed ID: 29960800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older.
    Neveu D; Mallett Moore T; Zambrano B; Chen A; Kürzinger ML; Marcelon L; Singh Dhingra M
    Infect Dis Ther; 2023 Oct; 12(10):2367-2386. PubMed ID: 37755671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study.
    Dhingra MS; Namazova-Baranova L; Arredondo-Garcia JL; Kim KH; Limkittikul K; Jantarabenjakul W; Perminova O; Kobashi IAR; Bae CW; Ojeda J; Park J; Chansinghakul D; B'Chir S; Neveu D; Bonaparte M; Jordanov E
    Epidemiol Infect; 2021 Apr; 149():e90. PubMed ID: 33814028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
    Peterson J; Drazan D; Czajka H; Maguire J; Pregaldien JL; Seppa I; Maansson R; O'Neill R; Balmer P; Jodar L; Jansen KU; Anderson AS; Perez JL; Beeslaar J
    Lancet Infect Dis; 2023 Dec; 23(12):1370-1382. PubMed ID: 37579773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.